Clinical Trial Update: Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the ELAD System for acute liver failure was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fulminant Hepatic Failure
• Graft Non-function
• Liver Failure
• Surgically-induced Liver Failure

Drugs mentioned

• ELAD System

Snippet

Sponsor: Vital Therapies, Inc. | Conditions: Acute Liver Failure, Fulminant Hepatic Failure | Phase 2 | Status: TERMINATED | Results posted: 2018-08-22